Plain-English translation of NCT05759546 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating advanced breast cancer by combining three medications: (a PARP inhibitor), (a CDK4/6 inhibitor), and hormone therapy. The study wants to see if adding to the other two medications helps patients live longer and feel better. This is an early-stage study with about 200 patients to prepare for a larger future trial.
Right now, doctors treat this type of advanced breast cancer with two medications, but researchers believe that adding this medication might work even better. This trial will help answer that question before testing it in a much larger group of patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly placed into one of two groups: one group will take three medications together (including the new medication being tested), and the other will take two medications. You will visit the clinic regularly for blood tests, scans, and check-ups to see how you are responding to treatment and to watch for side effects. The study team will monitor your progress closely over several months.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Collaborators
Peking University Cancer Hospital & Institute, First Hospital of China Medical University
Enrollment target
~200 participants
Started
February 2023
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhimin Shao
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.